Furthermore, we found that in samples from patients with ER+ metastatic disease, the abundance of ER negatively correlates with the abundance of GR, emphasizing that activation of GR signaling in these patients would confer a growth disadvantage on cancer cells, thereby preventing distant metastasis in ER+ disease. Here, ESR1 is linked to cancer.